dc.contributor.author | Gözüküçük, Ramazan | |
dc.contributor.author | Kılıç, Hasan Hüseyin | |
dc.date.accessioned | 2023-10-04T09:02:31Z | |
dc.date.available | 2023-10-04T09:02:31Z | |
dc.date.issued | 2023 | en_US |
dc.identifier.citation | Ramazan Gözüküçük, & Hasan Kılıç. (2023). The relationship between CMV reactivation, anti-cytokine treatment and mortality in critical COVID-19 patients. Pakistan Journal of Medical Sciences, 39(5). https://doi.org/10.12669/pjms.39.5.7301 | en_US |
dc.identifier.uri | http://dx.doi.org/10.12669/pjms.39.5.7301 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12941/154 | |
dc.description.abstract | Objective: To examine the use of anti-cytokine treatment in critical COVID-19 patients and their association with the frequency of CMV cases, viral load level, and mortality in these patients.
Methods: This is a retrospective study. A total of 170 critical and/or intensive care patients with COVID-19 admitted to Hisar Hospital Intercontinental from March 15, 2020, to December 31, 2021 were divided into the use of anti-cytokine treatment group and the no anti-cytokine treatment group. Furthermore, the relationship between CMV reactivation, mortality and anti-cytokine treatment in patients was also examined.
Results: A total of 170 critical COVID-19 patients were included in the study, three of them were excluded. One hundred sixty seven were included in the study of which 38 (22.7%) were found to be CMV DNA positive. As an anti-cytokine treatment, it was observed that tocilizumab was used in 53 patients, anakinra was used in 27 patients, and no anti-cytokine treatment was used in 77 patients. CMV positivity in patients treated with anti-cytokines (31.11%) was found to be significantly higher than in patients who were not treated with it (16.88%) (p:0.033). Furthermore, it was determined that anti-cytokine treatment significantly decreased mortality (p: 0.003) and that there was no significant relationship between CMV reactivation and mortality (p: 0.399).
Conclusion: Even though CMV reactivation was high in critical COVID-19 patients who received anti-cytokine treatment, decrease in mortality were observed with early diagnosis and effective treatment. Therefore, CMV infection should be considered in patients receiving immunosuppressive treatment.Clinical Trial Registration: HisarIH-101/NCT05419206. | en_US |
dc.language.iso | eng | en_US |
dc.relation.isversionof | 10.12669/pjms.39.5.7301 | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | Tocilizumab | en_US |
dc.subject | Anakinra | en_US |
dc.subject | Anti-cytokine treatment | en_US |
dc.subject | Mortality | en_US |
dc.subject | Cytomegalovirus (CMV) | en_US |
dc.subject | COVID-19 | en_US |
dc.title | The relationship between CMV reactivation, anti-cytokine treatment and mortality in critical COVID-19 patients | en_US |
dc.type | article | en_US |
dc.authorid | Ramazan Gözüküçük / 0000-0002-8205-4752 | en_US |
dc.department | Fakülteler, Diş Hekimliği Fakültesi, Temel Bilimler Bölümü | en_US |
dc.contributor.institutionauthor | Gözüküçük, Ramazan | |
dc.identifier.volume | 39 | en_US |
dc.identifier.issue | 5 | en_US |
dc.identifier.startpage | 1286 | en_US |
dc.identifier.endpage | 1290 | en_US |
dc.relation.journal | Pak J Med Sci | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |